FDA Recalls & Court Actions: June 20, 1990
CLASS II -- MUROMONAB-CD3 ORTHOCLONE OKT3 STERILE SOLUTION 5 mg (1 mg/1ml), for IV use only. Lot numbers: 19B007 EXP 11/89, 19D014 EXP 12/89, 68K111 EXP 7/89, 68L116 EXP 8/89, 68N129 EXP 9/89. Manufacturer: Ortho Pharmaceutical Corporation, Biotech Division, Raritan, New Jersey. Recalled by: Manufacturer, by telephone between Aug. 7, 1989 and Dec. 18, 1989. Firm-initiated recall complete. Distribution: Nationwide, Japan, Mexico, Switzerland. Firm estimates none remains on market. Reason: Product failed to maintain stability throughout the approved dating period.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth